1. Predictive markers for anthracycline benefit: a prospective planned analysis of the UK National Epirrubicin Adjuvant Trial (NEAT/BR9601);Bartlett;Lancet Oncol.,2010
2. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer;Coon;Clin. Cancer Res.,2002
3. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node positive breast cancer patients randomly treated either with an anthracycline-based or with cyclophosphamide, methotrexate, and 5-fluorouracil;Di Leo;Clin. Cancer Res.,2002
4. HER2 and TOPOIIA as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data;Di Leo;Lancet Oncol.,2011
5. Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel;Durbecq;Mol. Cancer Ther.,2004